Cargando…

The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer

BACKGROUND: The beneficial effects of radioactive iodine (RAI) ablation for intermediate-risk papillary thyroid cancer (PTC) patients are still controversial. MATERIALS AND METHODS: To determine the impact of RAI therapy on disease-specific survival (DSS) in patients with intermediate-risk PTC, we r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaofei, Zhu, Jingqiang, Li, Zhihui, Wei, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295195/ https://www.ncbi.nlm.nih.gov/pubmed/32542018 http://dx.doi.org/10.1371/journal.pone.0234843

Ejemplares similares

Radioactive iodine in low- to intermediate-risk papillary thyroid cancer
por: Zhao, Hengqiang, et al.
Publicado: (2022)

Radioactive iodine therapy may not improve disease‐specific survival in follicular variant papillary thyroid cancer without distant metastasis: A propensity score‐matched analysis
por: Wang, Xiaofei, et al.
Publicado: (2021)

Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis
por: Zhao, Min, et al.
Publicado: (2022)

Clinicopathological characteristics and recurrence risk of papillary thyroid microcarcinoma in the elderly
por: Wang, Xiaofei, et al.
Publicado: (2019)

“Adjuvant Radioactive iodine 133 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience”
por: AL-Qahtani, Khalid Hussain, et al.
Publicado: (2015)

Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib
por: Zayouna, Christine, et al.
Publicado: (2021)

Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer
por: Lee, Chang-Hee, et al.
Publicado: (2018)

BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer
por: Han, Sang-Ah, et al.
Publicado: (2014)

Erratum to: Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience
por: AL-Qahtani, Khalid Hussain, et al.
Publicado: (2016)

Radioactive Iodine Therapy Decreases Recurrence in Thyroid Papillary Microcarcinoma
por: Creach, Kimberly M., et al.
Publicado: (2012)

Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening
por: Sondorp, Luc H.J., et al.
Publicado: (2020)

Radioactive Iodine Ablation Decrease Recurrences in Papillary Thyroid Microcarcinoma with Lateral Lymph Node Metastasis in Chinese Patients
por: Xue, Shuai, et al.
Publicado: (2017)

Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to Treatment: Total Thyroidectomy with or without Radioactive Iodine Ablation
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Papillary thyroid cancer recurrence 43 Years following Total Thyroidectomy and radioactive iodine ablation: a case report
por: Amoako-Tuffour, Yaw, et al.
Publicado: (2017)

Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments
por: Mohamed, Ateesha F., et al.
Publicado: (2015)

The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas
por: Al-Kuraya, Khawla Sami, et al.
Publicado: (2021)

Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
por: Súss, Shirlei Kugler Aiçar, et al.
Publicado: (2018)

The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER
por: Tang, Jianing, et al.
Publicado: (2018)

Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer
por: Liu, Lina, et al.
Publicado: (2022)

How can we meet the information needs of patients with early stage papillary thyroid cancer considering radioactive iodine remnant ablation?
por: Sawka, A M, et al.
Publicado: (2011)

The Optimal Activity of Radioactive Iodine for Remnant Ablation in Low/Intermediate Risk Differentiated Thyroid Carcinoma: A Continuous Controversy and Meta-Analysis
por: Mirghani, Hyder, et al.
Publicado: (2021)

The prognostic value of the lymphocyte-to-monocyte ratio for high-risk papillary thyroid carcinoma
por: Song, Linlin, et al.
Publicado: (2019)

Risk factors associated with high thyroglobulin level following radioactive iodine ablation, measured 12 months after treatment for papillary thyroid carcinoma
por: Kim, Eun Young, et al.
Publicado: (2017)

Analysis of Curative Effect and Influencing Factors of N1 Stage Papillary Thyroid Micro-Carcinoma and Papillary Thyroid Non-Micro Carcinoma After Initial Radioactive Iodine Ablation Therapy
por: Yun, Canhua, et al.
Publicado: (2021)

The Diagnostic Accuracy of One-Step Nucleic Acid Amplification for Lymph Node Metastases of Papillary Thyroid Carcinoma： A Systematic Review and Meta-Analysis
por: Wang, Xiaofei, et al.
Publicado: (2022)

Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine
por: Adamska, Agnieszka, et al.
Publicado: (2021)

Responses to the First Radioactive Iodine Treatment After Targeted Therapy for Aggressive Papillary Thyroid Cancers
por: Soe, Myat Han, et al.
Publicado: (2021)

Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
por: Klain, Michele, et al.
Publicado: (2021)

A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol
por: Lee, Eun Kyung, et al.
Publicado: (2020)

Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer
por: Hu, Tianpeng, et al.
Publicado: (2016)

Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
por: Li, Wanting, et al.
Publicado: (2023)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy
por: Cao, Jingjia, et al.
Publicado: (2022)

First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report
por: Dao, Bao D., et al.
Publicado: (2015)

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience
por: Yasmin, Tahira, et al.
Publicado: (2021)

Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis
por: Wang, Chen, et al.
Publicado: (2017)

MON-494 Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to the Treatment: Total Thyroidectomy Versus Total Thyroidectomy with Radioactive Iodine Remnant Ablation
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer
por: Mu, Zhuan-Zhuan, et al.
Publicado: (2019)

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
por: Fullmer, Tanner, et al.
Publicado: (2021)

Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer - a randomized controlled trial
por: Sawka, Anna M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_u247eu3vjvlti7upc2fvjt9j1v